Ishibashi, Shun

Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017

Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis

Lipoproteins and Cardiovascular HealthHealth Promotion and Cardiovascular Prevention

Cited by 813

High cholesterol level is essential for myelin membrane growth

Saher, G., Brügger, B., Lappe-Siefke, C., Möbius, W., Tozawa, R.-I., Wehr, M. C., Wieland, F., Ishibashi, S., & Nave, K.-A. (2005) · Nature Neuroscience

Neurogenesis and neuroplasticity mechanismsCholesterol and Lipid Metabolism

Cited by 799

The two-receptor model of lipoprotein clearance: tests of the hypothesis in “knockout” mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins

Ishibashi, S., Herz, J., Maeda, N., Goldstein, J. L., & Brown, M. S. (1994) · Proceedings of the National Academy of Sciences

Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Cited by 430

Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression

Sekiya, M., Yahagi, N., Matsuzaka, T., Najima, Y., Nakakuki, M., Nagai, R., Ishibashi, S., Osuga, J.-I., Yamada, N., & Shimano, H. (2003) · Hepatology

Liver Disease Diagnosis and TreatmentFatty Acid Research and Health

Cited by 415

Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial

Ueki, K., Sasako, T., Okazaki, Y., Kato, M., Okahata, S., Katsuyama, H., Haraguchi, M., Morita, A., Ohashi, K., Hara, K., et al. (2017) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 313

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Ishibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., Suganami, H., Fruchart, J.-C., & Kodama, T. (2016) · Atherosclerosis

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 208

Serum Level of Triglycerides Is a Potent Risk Factor Comparable to LDL Cholesterol for Coronary Heart Disease in Japanese Patients with Type 2 Diabetes: Subanalysis of the Japan Diabetes Complications Study (JDCS)

Sone, H., Tanaka, S., Tanaka, S., Iimuro, S., Oida, K., Yamasaki, Y., Oikawa, S., Ishibashi, S., Katayama, S., Ohashi, Y., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health

Cited by 201

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Ishibashi, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Yamashita, S. (2018) · Journal of Clinical Lipidology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 184

Human Recombinant TNF Suppresses Lipoprotein Lipase Activity and Stimulates Lipolysis in 3T3-L1 Cells1

KAWAKAMI, M., MURASE, T., OGAMA, H., ISHIBASHI, S., MORI, N., TAKAKU, F., & SHIBATA, S. (1987) · The Journal of Biochemistry

Lipid metabolism and disordersLipid metabolism and biosynthesis

Cited by 183

Diet-induced hypercholesterolemia in mice: prevention by overexpression of LDL receptors

Yokode, M., Hammer, R. E., Ishibashi, S., Brown, M. S., & Goldstein, J. L. (1990) · Science

Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Cited by 175

Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2018) · Diabetes Care

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 164

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial

Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., Ishibashi, S., & on behalf of the K-877 Study Group (2018) · Journal of Atherosclerosis and Thrombosis

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 136

Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia

Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2017) · Atherosclerosis

Lipoproteins and Cardiovascular HealthPeroxisome Proliferator-Activated Receptors

Cited by 124

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment

Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 79

Leisure-time physical activity is a significant predictor of stroke and total mortality in Japanese patients with type 2 diabetes: analysis from the Japan Diabetes Complications Study (JDCS)

on behalf of the Japan Diabetes Complications Study Group, Sone, H., Tanaka, S., Tanaka, S., Suzuki, S., Seino, H., Hanyu, O., Sato, A., Toyonaga, T., Okita, K., et al. (2013) · Diabetologia

Physical Activity and HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 77

Close association of severe hyponatremia with exaggerated release of arginine vasopressin in elderly subjects with secondary adrenal insufficiency

Yatagai, T., Kusaka, I., Nakamura, T., Nagasaka, S., Honda, K., Ishibashi, S., & Ishikawa, S. (2003) · European Journal of Endocrinology

Electrolyte and hormonal disordersAdrenal Hormones and Disorders

Cited by 55

Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability?

Kusaka, I., Nagasaka, S., Horie, H., & Ishibashi, S. (2008) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 40

Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate

Yamashita, S., Okazaki, M., Okada, T., Masuda, D., Yokote, K., Arai, H., Araki, E., & Ishibashi, S. (2021) · Journal of Atherosclerosis and Thrombosis

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 14

A Pooled Analysis of Pemafibrate Phase II/III Clinical Trials Indicated Significant Improvement in Glycemic and Liver Function-related Parameters

Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S. (2018) · Atherosclerosis Supplements

Lipoproteins and Cardiovascular HealthMicroRNA in disease regulation

Cited by 11

Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial

Arai, H., Yamashita, S., Araki, E., Yokote, K., Tanigawa, R., Saito, A., Yamasaki, S., Suganami, H., & Ishibashi, S. (2024) · Journal of Atherosclerosis and Thrombosis

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 8

Effects of Selective PPARα Modulator K-877 on Particle Numbers of Lipoprotein Subclasses in Dyslipidemic Patients: Analysis by GP-HPLC and NMR Lipoprofile 2 and 3

Yamashita, S., Okazaki, M., Okada, T., Masuda, D., Arai, H., Yokote, K., Araki, E., & Ishibashi, S. (2018) · Atherosclerosis Supplements

Lipoproteins and Cardiovascular HealthPeroxisome Proliferator-Activated Receptors

Cited by 2